双鹭药业
(002038)
| 流通市值：64.32亿 | | | 总市值：77.56亿 |
| 流通股本：8.52亿 | | | 总股本：10.27亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 458,752,567.68 | 304,859,306.03 | 168,896,131.59 | 660,419,604.31 |
| 营业收入 | 458,752,567.68 | 304,859,306.03 | 168,896,131.59 | 660,419,604.31 |
| 二、营业总成本 | 442,623,429.84 | 290,269,767.12 | 155,955,363.45 | 621,412,318.94 |
| 营业成本 | 176,174,549.57 | 113,612,947.39 | 68,792,328.23 | 211,533,255.13 |
| 税金及附加 | 4,255,557.78 | 3,346,179.64 | 741,836.69 | 7,785,648.98 |
| 销售费用 | 73,477,652.02 | 45,723,204.76 | 19,904,477.41 | 117,181,775.5 |
| 管理费用 | 117,464,458.4 | 78,105,521.23 | 38,850,701.09 | 142,731,340.59 |
| 研发费用 | 75,104,850.67 | 52,662,971.39 | 28,942,931.49 | 149,623,443.03 |
| 财务费用 | -3,853,638.6 | -3,181,057.29 | -1,276,911.46 | -7,443,144.29 |
| 其中:利息收入 | 3,711,162.33 | 2,640,398.33 | 1,315,341.56 | 8,396,576.28 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 127,660,336.92 | 110,052,337.21 | 25,524,228.94 | -172,293,877.63 |
| 加:投资收益 | 12,155,587.41 | 10,278,335.2 | 5,591,921.67 | 13,127,545.13 |
| 资产处置收益 | 754.65 | 403.03 | - | - |
| 资产减值损失(新) | - | - | - | -556,697.75 |
| 信用减值损失(新) | -930,963.48 | -378,150.19 | 282,246.51 | -11,092,825.48 |
| 其他收益 | 7,015,840.55 | 4,884,714.44 | 4,006,991.45 | 12,205,218.38 |
| 四、营业利润 | 162,030,693.89 | 139,427,178.6 | 48,346,156.71 | -119,603,351.98 |
| 加:营业外收入 | 5.59 | 1.66 | 0.23 | 70,826.98 |
| 减:营业外支出 | 3,170,977.46 | 3,166,977.46 | 323,036 | 14,217,127.64 |
| 五、利润总额 | 158,859,722.02 | 136,260,202.8 | 48,023,120.94 | -133,749,652.64 |
| 减:所得税费用 | 18,229,121.33 | 15,637,333.74 | 2,405,937.61 | -58,462,889.66 |
| 六、净利润 | 140,630,600.69 | 120,622,869.06 | 45,617,183.33 | -75,286,762.98 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 140,630,600.69 | 120,622,869.06 | 45,617,183.33 | -75,286,762.98 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 141,098,044.78 | 121,048,202.7 | 45,968,405.62 | -74,065,657.76 |
| 少数股东损益 | -467,444.09 | -425,333.64 | -351,222.29 | -1,221,105.22 |
| 扣除非经常损益后的净利润 | 29,334,879.14 | 26,004,427.82 | 21,141,816.5 | 82,336,980.01 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.14 | 0.12 | 0.04 | -0.07 |
| (二)稀释每股收益 | 0.14 | 0.12 | 0.04 | -0.07 |
| 九、综合收益总额 | 140,630,600.69 | 120,622,869.06 | 45,617,183.33 | -75,286,762.98 |
| 归属于母公司股东的综合收益总额 | 141,098,044.78 | 121,048,202.7 | 45,968,405.62 | -74,065,657.76 |
| 归属于少数股东的综合收益总额 | -467,444.09 | -425,333.64 | -351,222.29 | -1,221,105.22 |
| 公告日期 | 2025-10-27 | 2025-08-26 | 2025-04-22 | 2025-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |